Ablation of atrial fibrillation with left atrial scar

Atrial fibrillation (AF) ablation is often considered when symptoms persist despite medication, when antiarrhythmic drugs are poorly tolerated, or when rhythm control is clinically important. The procedure is more complex when the left atrium contains fibrotic or scarred tissue. In this setting, pulmonary vein isolation remains central, but the probability of durable sinus rhythm depends on the biological substrate surrounding the veins.

Left atrial scar may reflect previous ablation, longstanding AF, atrial dilation, heart failure, valvular disease, inflammation, or ageing-related remodelling. It can be identified through late gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMR), low-voltage electroanatomical mapping, or a combination of imaging and procedural findings. These methods do not always measure exactly the same feature, so interpretation requires clinical context.

For Australian patients, prognosis also sits within practical realities: access to high-volume electrophysiology services is concentrated in cities such as Sydney, Melbourne, Brisbane and Perth, while patients in regional and remote areas may travel considerable distances for procedures and follow-up. Public hospital pathways, private insurance, Medicare-supported consultations and the availability of cardiac MRI can all influence the timing and continuity of care.

Why left atrial scar changes the rhythm strategy

A healthy atrium conducts electrical impulses in a relatively organised way. Scar interrupts conduction, creates areas of slow propagation, and may support small re-entry circuits. Fibrotic tissue can also separate surviving muscle bundles, allowing electrical activity to persist after the pulmonary veins have been isolated. This helps explain why patients with a substantial scar burden have higher rates of recurrent AF, atrial tachycardia and repeat procedures.

The location of scar matters as much as its overall quantity. Extensive anterior, septal, roof or posterior wall disease may indicate a more advanced atrial cardiomyopathy. Patchy scar can create channels between electrically silent regions, while dense confluent scar may reduce the available atrial tissue but still leave arrhythmogenic borders. A procedural map therefore provides more useful information than a simple label of “scar present” or “scar absent.”

Scar is also a marker of the conditions that caused atrial remodelling. Persistent AF, hypertension, obesity, sleep apnoea, diabetes, alcohol exposure and heart failure may continue to drive progression after ablation. The ablation result is consequently influenced by both lesion delivery and the ongoing management of atrial disease.

Scar burden and distribution as prognostic markers

The percentage of the left atrial wall showing delayed enhancement on CMR has been studied as a predictor of post-ablation recurrence. Greater fibrosis generally corresponds to a lower chance of maintaining sinus rhythm, although thresholds vary between imaging systems, segmentation methods and institutions. A numerical percentage should not be treated as an absolute prediction for an individual patient.

The pattern of scar may be particularly informative. Heterogeneous regions with viable myocardium interspersed among fibrotic tissue can form conduction channels and promote organised atrial tachycardias. Low-voltage areas identified during the procedure may reveal disease that is underestimated by imaging, especially in patients with previous ablation or marked atrial enlargement.

Imaging quality is relevant to prognosis. CMR availability differs between Australian metropolitan and regional services, and not every patient can undergo it because of renal impairment, device compatibility, claustrophobia or local expertise. When LGE-CMR is unavailable or uncertain, a detailed voltage map, echocardiography and the patient’s clinical trajectory can still support a practical risk assessment.

Clinical factors that shape recurrence risk

AF type is a major prognostic factor. Patients with paroxysmal AF and limited structural disease tend to have more favourable outcomes than those with persistent or longstanding persistent AF. A long duration of continuous AF suggests electrical and structural remodelling that may not reverse quickly after cardioversion or pulmonary vein isolation.

Left atrial volume, left ventricular function and valvular disease also affect outcomes. Mitral regurgitation, mitral stenosis, hypertrophic cardiomyopathy and heart failure can increase atrial pressure and stretch. A large left atrium often reflects accumulated disease rather than an isolated measurement, making it a useful indicator of the substrate’s maturity.

Modifiable factors deserve the same attention as procedural findings. Weight reduction, blood pressure control, treatment of obstructive sleep apnoea, reduced alcohol intake, regular physical activity and diabetes management can improve rhythm outcomes. Australian care may involve coordination between electrophysiologists, general practitioners, cardiologists, sleep physicians and cardiac rehabilitation teams, particularly when patients move between metropolitan and regional services.

Procedural endpoints and technique

Pulmonary vein isolation remains the foundation of catheter ablation for AF. Confirming entrance and exit block is important, because recovered pulmonary vein conduction is a common mechanism of recurrence. In patients with significant left atrial scar, operators may also assess low-voltage regions and inducible atrial tachycardias, but broad empirical substrate modification must be balanced against the risk of creating new organised circuits.

Additional ablation of the posterior wall, complex fractionated electrograms or linear lesions may be appropriate in selected patients, especially when documented atrial tachycardia or clearly defined re-entry is present. However, extensive lesion sets do not automatically improve outcomes for every patient with scar. Incomplete lines can become channels for macro-re-entry, and unnecessary ablation may increase procedure time and the need for repeat intervention.

Energy source and procedural platform may influence lesion durability, though patient selection and operator experience remain crucial. Radiofrequency, cryoballoon and newer pulsed-field approaches each have different technical characteristics, safety considerations and evidence bases. The Australian market includes public and private electrophysiology programs with varying access to these technologies, so a treatment plan should reflect local expertise rather than technology branding alone.

Follow-up, recurrence and repeat intervention

Early atrial arrhythmias after ablation do not always represent final treatment failure. Inflammation and transient autonomic changes can produce episodes during the blanking period. Recurrent symptoms still warrant assessment because sustained AF, atrial flutter and atrial tachycardia may require cardioversion, medication adjustment or closer monitoring.

Intermittent symptoms can be missed by a standard clinic electrocardiogram. Wearable monitors, patch monitors, implantable loop recorders and pacemaker or defibrillator diagnostics may provide a clearer estimate of AF burden. The clinical meaning of recurrence also depends on duration, symptoms, ventricular response, anticoagulation status and effects on ventricular function. Research on arrhythmia burden data illustrates why episode frequency and duration can carry prognostic information beyond a single rhythm snapshot.

Repeat ablation is sometimes reasonable when pulmonary vein reconnection, a defined atrial tachycardia or a persistent symptomatic arrhythmia is documented. It is less likely to help when advanced scar, uncontrolled risk factors or severe comorbidity dominate the clinical picture. Shared decision-making should address the chance of another procedure, anaesthetic and vascular risks, time away from work, travel from areas such as regional New South Wales or Far North Queensland, and the patient’s priorities.

Anticoagulation and long-term risk management

Successful rhythm control does not automatically remove thromboembolic risk. Decisions about oral anticoagulation should be guided by validated stroke-risk assessment and the patient’s bleeding risk, rather than by the apparent absence of AF after ablation. Some patients require anticoagulation indefinitely, particularly when age, hypertension, heart failure, diabetes, previous stroke or vascular disease contributes to risk.

Antiarrhythmic medication may be used before or after the procedure, depending on symptoms, structural heart disease and recurrence pattern. Rate-control therapy can remain useful even when sinus rhythm is the principal goal. Medication access through the Pharmaceutical Benefits Scheme may influence prescribing and adherence, while renal function, interactions and monitoring requirements need regular review.

Device patients require additional care. Palpitations after ablation may reflect atrial tachycardia, inappropriate therapy or another rhythm rather than recurrent AF alone. The mechanisms behind ICD shock events reinforce the value of device interrogation and careful discrimination of supraventricular and ventricular rhythms. Patients with implanted devices should have a clear pathway to their device clinic, especially when travelling between Australian states or living far from a tertiary hospital.

Prognosis is best estimated through a combined assessment: scar burden and pattern, AF duration, atrial size, ventricular function, comorbidities, procedural endpoints and post-ablation monitoring. No single scan or mapping value can replace that integrated view. For clinicians and trainees, careful phenotyping helps determine who is most likely to benefit from first-line ablation, who may need staged treatment, and who requires aggressive risk-factor modification before intervention.

Electrophysiology teams can use this framework to refine consent discussions and follow-up plans for patients with left atrial scar. Clinicians, researchers and trainees are encouraged to review current evidence through the Journal of Arrhythmia and apply emerging imaging, mapping and ablation data to locally appropriate care.